Evidence map›Paper›PMID 42637754›Full record

ArticleNature communications2026

Spatial transcriptomics reveals distinct cell type dynamics following opioid dependence in female mice with the common human μ-opioid receptor variant Oprm1 A118G.

Yihan Xie, Anna K Leonard, Omar Guessoum, Kyle A Windisch, Johnathan Schug, Hilana El-Mekkoussi, Adrienne Jo, D Kacy Cullen, Klaus H Kaestner, Julie A Blendy

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Yihan XieDepartments of System Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0009-0002-3084-3204
Anna K LeonardDepartments of System Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Omar GuessoumDepartment of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Kyle A WindischDepartments of System Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Johnathan SchugDepartment of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Hilana El-MekkoussiDepartment of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Adrienne JoDepartments of System Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
D Kacy CullenDepartment of Bioengineering, School of Engineering and Applied Science, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-5355-5216
Klaus H KaestnerDepartment of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-1228-021X
Julie A BlendyDepartments of System Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. blendy@pennmedicine.upenn.edu.ORCID http://orcid.org/0000-0003-1705-9001

Funding

Circuitry dynamics underlying opioid-dependence: Integrating structural, functional, and transcriptomic mechanismsR01DA056599 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI KEVIN T BEIER, Julie A Blendy · 2022 to 2026
$3.8M
Mapping opioid-dependence state transitions across structural, functional, and transcriptomic topologiesR01DA054374 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI BLENDY, JULIE A, CORDER, GREGORY · 2021 to 2025
$2.4M
NIDA NIH HHS R01 DA054374NIDA NIH HHS R01 DA056599U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) GM159555U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA) DA054374U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA) DA056599
6 · The paper itself

Abstract

Opioid Use Disorder (OUD) is a complex neuropsychiatric condition shaped by multiple factors including genetics. The A118G single-nucleotide polymorphism (rs1799971) in the µ-opioid receptor gene (OPRM1) has been associated with heightened risk for opioid and other substance dependencies, but the molecular basis of this effect remains unclear. Importantly, mice with the orthologous SNP, Oprm1 A112G, recapitulate many of the divergent behavioral responses to opioids documented in humans with the same variant. To probe how these variants influence opioid dependence at a cellular and molecular level, we performed single-nucleus spatial transcriptomic analyses of cell-type composition and cell-state/transcriptional programs in Oprm1 A112G mice with and without morphine dependence. A key discovery from our study is that opioid-induced changes in cell type transcriptomic states varied markedly by genotype. Specifically, transcriptomic alterations during opioid dependence were reflected more prominently in glial populations rather than in neurons specifically in the Oprm1 GG mice. By combining gene co-expression, pathway activity, and network remodeling across cell types and regions, we link Oprm1-driven genetic risk to anatomically organized shifts in glial, neuronal, and network function, defining the molecular basis of opioid dependence shaped by genetic background.

Indexed as

Opioid-Related DisordersReceptors, Opioid, muAnimalsFemaleGenotypeHumansMiceMice, Inbred C57BLNeurogliaNeuronsPolymorphism, Single NucleotideSpatial TranscriptomicsTranscriptomeOPRM1 protein, humanOprm protein, mouseReceptors, Opioid, mu

Identifiers

PMID42637754
PMCPMC13503859

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.